Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

Journal of Translational Medicine

Meeting Report

G. Masucci¹  C. B. Bifulco²  G. Ciliberto³  T. Rau⁴  J. Galon⁵  B. A. Fox⁶  F. M. Marincola⁷  P. A. Ascierto⁸  M. Capone⁸  G. Botti⁹  F. Pages^1,10 

[1] Department of Oncology-Pathology, The Karolinska Hospital, Stockholm, Sweden;Department of Pathology, Providence Portland Medical Center, 97213, Portland, OR, USA;IRCCS, Istituto Nazionale Tumori, Fondazione “G. Pascale”,Scentific Directorate, Naples, Italy;Institute of Pathology, University of Bern, Bern, Switzerland;Laboratory of Integrative Cancer Immunology, INSERM UMRS1138 Cordeliers Research Center, University Pierre et Marie Curie, Paris 6, 15 Rue de l’Ecole de Medecine, 75006, Paris, France;University Paris Descartes, 45 Rue Saints Pères, 75006, Paris, France;Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, 97213, Portland, OR, USA;Department of Molecular Microbiology & Immunology, Oregon Health & Science University, 97239, Portland, OR, USA;Sidra Medical and Research Center, Doha, Qatar;Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori, Fondazione “G. Pascale”, Naples, Italy;Unit of Pathology, IRCCS, Istituto Nazionale Tumori, Fondazione “G. Pascale”, Naples, Italy;University Paris Descartes, 45 Rue Saints Pères, 75006, Paris, France;Laboratory of Integrative Cancer Immunology, INSERM UMRS1138, Cordeliers Research Center, 15 Rue de l’Ecole de Medecine, 75006, Paris, France;Centre de Recherche des Cordeliers, University Pierre et Marie Curie, Paris 6, 15 Rue de l’Ecole de Medecine, 75006, Paris, France;Immunomonitoring Platform, Laboratory of Immunology, Georges Pompidou European Hospital, 20-40 Rue Leblanc, 75015, Paris, France;

关键词: Melanoma;    Immunoscore;    Immunoprofiling;   

DOI  :  10.1186/s12967-016-1029-z

 received in 2016-08-05, accepted in 2016-09-06,  发布年份 2016

来源: Springer

【 摘 要 】

The fifth “Melanoma Bridge Meeting” took place in Naples, December 1–5th, 2015. The main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies and Combination Therapies, Tumor Microenvironment and Biomarkers and Immunoscore. The natural history of cancer involves interactions between the tumor and the immune system of the host. The immune infiltration at the tumor site may be indicative of host response. Significant correlations were shown between the levels of immune cell infiltration in tumors and patient’s clinical outcome. Moreover, incredible progress comes from the discovery of mutation-encoded tumor neoantigens. In fact, as tumors grow, they acquire mutations that are able to influence the response of patients to immune checkpoint inhibitors. It has been demonstrated that sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. The road ahead is still very long, but the knowledge of the mechanisms of immune escape, the study of tumor neo-antigens as well as of tumor microenvironment and the development of new immunotherapy strategies, will make cancer a more and more treatable disease.

【 授权许可】

CC BY   
© The Author(s) 2016